BLEJK Dzhim (US),БЛЭЙК Джим (US),CHEN Khojfen (US),ЧЭНЬ Хойфэнь (US),CHIKARELLI Mark (US),ЧИКАРЕЛЛИ Марк (US),GAUDINO Dzhon (US),ГАУДИНО Джон (US),GAZZARD Lyuis (US),ГАЗЗАРД Льюис (US),KINTZ Sem (US),BLEJK Dzhim,БЛЭЙК Джим,CHEN Khojfen,ЧЭНЬ Хойфэнь,CHIKARELLI Mark,ЧИКАРЕЛЛИ Марк,GAUDINO Dzhon,ГАУДИНО Джон,GAZZARD Lyuis,ГАЗЗАРД Льюис,KINTZ Sem,КИНТЗ Сэм,MOR Pit,МОР Пит,ROBARDZH Kirk,РОБАРДЖ Кирк,SH
申请号：
RU2015110985
公开号：
RU0002644947C2
申请日:
2013.08.27
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: chemistry.SUBSTANCE: invention relates to the field of organic chemistry, namely a heterocyclic compound of formula (I) or a stereo-isomer thereof or a pharmaceutically acceptable salt, where X is CH or N； Z is (i) NH(CH2)nCHR1Ar, where n is 0 or 1, or (ii) is 1-alkyl-4-aryl-pyrrolidin-3-ylamine, where alkyl is C1 alkyl, optionally substituted with a phenyl ring, and aryl is methoxy substituted phenyl； R1 is (a) hydrogen, (b) C1-C6 alkyl optionally substituted with a hydroxyl group, (c) from 4 to 5 member heterocycle containing 1 hetero atom selected from N, where the heterocycle is optionally substituted with one group selected from the group consisting of halogen, or (d) 5 member heteroaryl containing 1 or 2 hetero atoms selected from N, where heteroaryl is optionally substituted with one group selected from C1-6 alkyl； Ar is phenyl, pyridinyl or indolyl optionally substituted with from 1 to 2 groups independently selected from (a) C1-6 alkoxy, (b) halogen, (c) C1-6 halogenalkoxy, (d) cyano, (e) benzyl, (f) phenoxy, where said phenoxy is optionally substituted with halogen or C1-6 alkyl, (g) 4-methylpiperazin-1-yl or (h) heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl and pyrazolyl, where said heteroaryl is optionally substituted with one C1-10 alkyl； R2 is selected from the group consisting of (a) C1-5 hydroxyalkyl, (b) C1-6 haloalkyl, (c) heterocyclyl, where said heterocyclyl is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, 2-oxa-bicyclo[2,2,1]heptan-5-yl and pyrrolidinyl, and where said heterocyclyl is optionally substituted with 1 group independently selected from the group consisting of halogen, C1-3 hydroxyalkyl or oxo, (d) heteroaryl, where said heteroaryl is selected from the group consisting of pyrazolyl and pyridinyl, and where said heteroaryl is optionally substituted with 1-2 C1-3 alkyl groups, (e) C3 cycloalkyl-C1-2 alkyl, where said C3 cycloalkyl-C1-2 alkyl is optionally substitu
